奥沙利铂联合卡培他滨治疗晚期原发性肝癌的临床观察

目的观察奥沙利铂(OXA)联合卡培他滨(CAP)治疗晚期肝癌效果及药物毒性反应。方法我院2008年6月至2011年6月收治的40例经细胞学或影像学证实的晚期肝癌患者,随机分为观察组20例:OXA+CAP方案;对照组20例:FOLFOX6方案(OXA+CF+5-Fu);治疗2周期后进行疗效评估。结果对照组ORR为5%,DCR为55%;TTP为2.1月,MST为9月,半年生存率为33%;观察组ORR为10%,DCR为50%;TTP为2.7月,MST为10月,半年生存率为38%;虽然观察组疗效较对照组稍高,但两组疗效差异无统计学意义(P>0.05);观察组手足综合征明显高于对照组,但对照组消化道反应、血液学毒性反应均高于观察组,二者差异就有统计学意义(P<0.05);比较两组肝肾功能损害,两组无明显差异(P>0.05)。结论奥沙利铂为基础的联合化疗方案对晚期肝癌显示较好抗肿瘤效果,应根据患者实际情况选择最佳化疗方案。

Clinical Observation on the Effect of Oxaliplatin Conbined with Capecitabine in Treating Advanced Primary Liver Cancer

Objective To observe and analyze the efficacy and toxic reaction of the oxaliplatin (OXA) combined with capecitabine (CAP) in treatment of patients with advanced primary liver cancer. Methods 40 patients with advanced primary liver cancer confirmed by cytology or imageology in our hospital from June 2008 to June 2011 were randomly divided into the observation group (20 cases, OXA + CAP) and the control group (20 cases, OXA + CF + 5-FU). The curative effects were evaluated after 2 cycles of therapy. Results The overall response rate (ORR), disease control rate (DCR), time to progression (TTP), median survival time (MST) and half year survival rate was 5%, 55%, 2.1 months, 9 months and 33% in the observation group, while 10%, 50%, 2.7 months, 10 months and 38% in the control group; the diffenences between the two groups had no statistical significance (P >0.05). The hand-foot syndrome in the observation group was significantly higher than that in the control group, but the gastrointestinal reaction, hematologic toxicity reaction in the control group were higher than those in the observation group (P <0.05). The differences of liver and kidney function damage between the two groups had no statistical significance (P >0.05). Conclusions The combined chemotherapy regimen based on the oxaliplatin shows good anti-tumour effect for advanced primary liver cancer. The optimal chemotherapy regimen should be chosen according to patients’ actual condition.